Biosimilars Canada Boss Calls For Ontario Switching Policy
Jim Keon Urges Ontario To Follow Other Provinces And Adopt Biosimilar Switching Program
Biosimilars Canada president Jim Keon has urged the province of Ontario to follow other Canadian provinces by adopting a biosimilar switching policy for its public drug program, in order to cut costs on biologics and re-invest in the healthcare system.
You may also be interested in...
Ontario has joined several other Canadian provinces and territories by implementing a biosimilar switching policy for Ontarians taking biologic drugs.
Biosimilars Canada has renewed its call for Ontario to adopt a biosimilar switching policy in line with other Canadian provinces and territories, suggesting that Ontario alone could save CAD147m annually through such a scheme.
The first biosimilar approval stemming from Alvotech’s collaboration with JAMP Pharma in Canada has arrived, with the firms’ Simlandi (adalimumab) biosimilar version of AbbVie’s higher-strength Humira. Celltrion has also announced an approval from Health Canada.